Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Deferred Revenue (2016 - 2022)

Agios Pharmaceuticals (AGIO) has disclosed Current Deferred Revenue for 10 consecutive years, with $2.5 million as the latest value for Q1 2022.

  • For Q1 2022, Current Deferred Revenue changed N/A year-over-year to $2.5 million; the TTM value through Mar 2022 reached $2.5 million, changed N/A, while the annual FY2019 figure was $61.5 million, 33.51% down from the prior year.
  • Current Deferred Revenue hit $2.5 million in Q1 2022 for Agios Pharmaceuticals, up from $306000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $92.5 million in Q4 2018 and bottomed at $306000.0 in Q1 2020.
  • Average Current Deferred Revenue over 4 years is $25.9 million, with a median of $16.9 million recorded in 2019.
  • Year-over-year, Current Deferred Revenue plummeted 98.09% in 2018 and then soared 2852.64% in 2019.
  • Agios Pharmaceuticals' Current Deferred Revenue stood at $92.5 million in 2018, then tumbled by 33.51% to $61.5 million in 2019, then plummeted by 99.5% to $306000.0 in 2020, then surged by 716.99% to $2.5 million in 2022.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $2.5 million, $306000.0, and $61.5 million for Q1 2022, Q1 2020, and Q4 2019 respectively.